November 14, 2012 (v1)
Journal article
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib.
The advent of tyrosine kinase inhibitor (TKI) therapy has considerably improved the survival of patients suffering chronic myelogenous leukemia (CML). Indeed, inhibition of BCR-ABL by imatinib, dasatinib or nilotinib triggers durable responses in most patients suffering from this disease. Moreover, resistance to imatinib due to kinase domain...
Uploaded on: December 4, 2022